Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AlloVir gets $121mm via Series B

Executive Summary

AlloVir Inc. (formerly ViraCyte; developing cell therapies for virus-associated diseases) raised $121mm through its Series B financing led by Fidelity Management and Research Co., which was joined by Gilead Sciences (adds a board observer), F2 Ventures (adds a director), Redmile Group, Invus, EcoR1 Capital, Samsara BioCapital, and Leerink Partners. AlloVir will use the proceeds for Phase III trials of its lead antiviral program Viralym-M (ALVR105).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register